Cardior Pharmaceuticals

Cardior Pharmaceuticals is a leading clinical-stage biopharmaceutical company pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart. Cardiors therapeutic approach uses distinctive non-coding RNAs as an innovative platform for addressing the root causes of cardiac dysfunctions. The company aspires to bring transformative therapeutics and diagnostics to patients and thereby make a lasting impact on the treatment of cardiac diseases worldwide. As of May 2, 2024 Cardior Pharmaceuticals GmbH is a wholly owned subsidiary of Novo Nordisk Region Europe A/S

Therapeutics,non-coding rnas,oligonucleotides,microrna,lncrna,and heart failure

Cardior pharmaceuticals operates in the Pharmaceutical manufacturing industry.

Cardior pharmaceuticals's revenue is 11m - 100m

Cardior pharmaceuticals has 11 - 50 employees.